Werewolf Therapeutics, Inc.
Werewolf Therapeutics is an innovative biotech company dedicated to transforming cancer treatment through targeted immunotherapies. They develop systemically delivered, conditionally activated immune modulators called INDUKINE™ molecules, utilizing proprietary PREDATOR™ protein engineering technology. Their goal is to unleash immune responses specifically within tumors while minimizing off-target effects, aiming to improve outcomes for cancer patients.
Industries
Nr. of Employees
small (1-50)
Werewolf Therapeutics, Inc.
Patents
Products
Conditionally activated IL-2 therapeutic (first-in-human, early-phase clinical program)
Systemically administered, conditionally activated IL-2 prodrug designed to maintain IL-2 potency in tumors while reducing systemic toxicity; being evaluated in a Phase 1/1b dose-escalation and expansion trial including combination arms with checkpoint inhibitors.
Conditionally activated IL-12 therapeutic (IND/early clinical development)
Systemically administered, conditionally activated IL-12 prodrug designed to block systemic receptor interactions and enable tumor-selective activation with half-life extension for optimal tumor exposure; clinical dose/regimen optimization trials planned.
Conditionally activated IL-21 and IL-18 therapeutics (preclinical/partnering)
Preclinical conditionally activated IL-21 and IL-18 designs that aim to increase tumor immune infiltration and CD8+ T cell function (IL-21) and to enable IL-18 activity with reduced systemic effects; available for partnering.
Conditionally activated therapeutics for inflammatory diseases
Application of conditional-activation platform to non-oncology indications (example: IL-10 approach for inflammatory bowel disease) with the aim of tissue-specific modulation of inflammation while minimizing off-target effects.
Masked and tumor‑targeted T cell engager and ADC approaches
Platform applications to masked tumor-targeted T cell engager designs and antibody-drug conjugates that incorporate conditional activation or disease-specific linkers.
Conditionally activated IL-2 therapeutic (first-in-human, early-phase clinical program)
Systemically administered, conditionally activated IL-2 prodrug designed to maintain IL-2 potency in tumors while reducing systemic toxicity; being evaluated in a Phase 1/1b dose-escalation and expansion trial including combination arms with checkpoint inhibitors.
Conditionally activated IL-12 therapeutic (IND/early clinical development)
Systemically administered, conditionally activated IL-12 prodrug designed to block systemic receptor interactions and enable tumor-selective activation with half-life extension for optimal tumor exposure; clinical dose/regimen optimization trials planned.
Conditionally activated IL-21 and IL-18 therapeutics (preclinical/partnering)
Preclinical conditionally activated IL-21 and IL-18 designs that aim to increase tumor immune infiltration and CD8+ T cell function (IL-21) and to enable IL-18 activity with reduced systemic effects; available for partnering.
Conditionally activated therapeutics for inflammatory diseases
Application of conditional-activation platform to non-oncology indications (example: IL-10 approach for inflammatory bowel disease) with the aim of tissue-specific modulation of inflammation while minimizing off-target effects.
Masked and tumor‑targeted T cell engager and ADC approaches
Platform applications to masked tumor-targeted T cell engager designs and antibody-drug conjugates that incorporate conditional activation or disease-specific linkers.
Services
Design and execution of first‑in‑human dose-escalation and dose-expansion studies, including combination trials with checkpoint inhibitors and multicenter site coordination.
Opportunities to partner on preclinical and clinical-stage programs and to apply conditional-activation engineering to third-party programs.
Design and execution of first‑in‑human dose-escalation and dose-expansion studies, including combination trials with checkpoint inhibitors and multicenter site coordination.
Opportunities to partner on preclinical and clinical-stage programs and to apply conditional-activation engineering to third-party programs.
Expertise Areas
- Immuno-oncology therapeutics
- Protein engineering for conditional activation
- Cytokine prodrug development
- Early‑phase clinical development (Phase 1/1b, Phase 1/2)
Key Technologies
- Conditional prodrug design
- Protease‑cleavable linker design
- Half‑life extension domain engineering
- Cytokine engineering
News & Updates
Werewolf Therapeutics announced their participation in the BIO International Convention on June 12, 2025.
The company announced their participation in the Jefferies Global Healthcare Conference on May 29, 2025.
A patient with advanced skin cancer has been in remission for over a year following a clinical trial involving WTX-124.
Werewolf Therapeutics announced their participation in the BIO International Convention on June 12, 2025.
The company announced their participation in the Jefferies Global Healthcare Conference on May 29, 2025.
A patient with advanced skin cancer has been in remission for over a year following a clinical trial involving WTX-124.